Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema

NCT00576459 | Completed Phase 2

• 1 other identifier: 420-003
• Study Type: interventional
• Target: 40
• Locations: 2 countries
• Sites: 2

Brief Summary

This is a 3-year randomized, dose masked, three-arm controlled, pilot study to evaluate the safety and efficacy of the intravitreal FA implants (0.59mg and 2.1mg), when compared to laser photocoagulation in the treatment of patients with diabetic macular edema.

Conditions

Diabetic Macular Edema

Outcome Measures

Primary Outcomes (1)

• Between group difference in mean visual acuity change (from baseline)

  1 year

Secondary Outcomes (2)

• Differences in the proportions of subjects in each treatment group experiencing changes in: the area of retinal thickening; retinal leakage and cystoid scores; grade of diabetic retinopathy

  1 year

• Ocular adverse events, non-ocular adverse events, and intraocular pressure >/= 30 mm Hg

  throughout study

Study Arms (3)

Fluocinolone acetonide 0.59 mg

EXPERIMENTAL

0.59 mg fluocinolone acetonide intravitreal implant

Drug: 0.59 mg fluocinolone acetonide intravitreal implant

Fluocinolone acetonide 2.1 mg

EXPERIMENTAL

2.1 mg fluocinolone acetonide intravitreal implant

Drug: 2.1 mg fluocinolone acetonide intravitreal implant

Laser photocoagulation

ACTIVE COMPARATOR

standard of care laser photocoagulation

Procedure: standard of care laser photocoagulation

Interventions

0.59 mg fluocinolone acetonide intravitreal implant DRUG

0.59 mg

Also known as: Retisert

Fluocinolone acetonide 0.59 mg

2.1 mg fluocinolone acetonide intravitreal implant DRUG

2.1 mg

Fluocinolone acetonide 2.1 mg

standard of care laser photocoagulation PROCEDURE

standard of care laser photocoagulation

Laser photocoagulation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with type 1 or 2 diabetes.
• Subjects with clinically significant macular edema as defined by the ETDRS.
• A best corrected visual acuity between +0.30 and +1.00 logMAR (70 and 35 letters or approximately 20/40 to 20/200) as measured on an ETDRS chart.
• Subjects with laser treatment status/history as follows: \[1\] Naïve to laser photocoagulation or Focal laser photocoagulation more than 16 weeks prior to screening or PRP more than 24 weeks prior to screening, \[2\] No laser scars within 500µm (4x the width of a retinal vein at the disc margin) of the central macula.
• The subject's ocular media had to be sufficiently clear to allow for quality fundus photography.
• If aphakic or pseudophakic, lens removal had to have occurred at least 40 weeks prior to screening.
• Subjects had to be males or non-pregnant females of at least 18 years.
• Subjects had to display the ability and willingness to comply with treatment, follow up process, and sign an Informed Consent Form.

You may not qualify if:

• Subjects who have had previous grid macular photocoagulation for diffuse macular edema.
• Presence of posterior hyaloid membrane, epiretinal membranes, fibrovascular proliferation, and vitreopapillary traction, which causes tractional distortion on the macula as demonstrated by OCT or funduscopy.
• History of or current retinal detachment requiring surgical treatment or a scleral buckle.
• Diabetic Retinopathy that required immediate PRP.
• Ocular disease other than diabetic retinopathy that could confound the outcome of the study (e.g., age-related macular degeneration, drug toxicity, uveitis, hypertensive retinopathy, ischemic maculopathy, etc.).
• Glaucoma, or history of glaucoma in either the study eye or the fellow eye.
• Ocular hypertension, or history of ocular hypertension requiring IOP lowering treatment.
• A media opacity that precludes visualization and/or diagnosis of the status of the eye.
• Concurrent coumadin therapy or known bleeding diathesis.
• Subjects requiring chronic systemic corticosteroid therapy or systemic immunosuppressive therapy to manage non-ocular disease.
• Concurrent treatment with a new investigational drug.
• Subjects with a best-corrected visual acuity worse than +1.0 logMAR (20/200 or 35 ETDRS letters) in the fellow eye.
• Pregnant or lactating females.
• Females of childbearing potential considering becoming pregnant during the course of the study and those not taking effective contraception/precautions to avoid pregnancy.
• History of hypersensitivity to fluorescein, known allergies to steroids or any component of the intraocular device.

Sponsors & Collaborators

• Bausch & Lomb Incorporated: lead

Study Sites (2)

The Chinese University of Hong Kong

Hong Kong, China

Location

LV Prasad Eye Institute

Banjara Hills, Hyderabad, 500 034, India

Location

MeSH Terms

Interventions

Fluocinolone Acetonide

Intervention Hierarchy (Ancestors)

Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated

Study Officials

• Taraprasad Das, MD

  LV Prasad Eye Institute

  PRINCIPAL INVESTIGATOR

• Dennis Lam Shun-Chiu, MD

  Chinese University of Hong Kong

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 18, 2007
• First Posted: December 19, 2007
• Study Start: March 1, 2003
• Primary Completion: June 1, 2006
• Study Completion: July 1, 2006
• Last Updated: December 8, 2011

Record last verified: 2011-07

Locations

IN (1); CN (1)